NCT06711302: REPAIR

Remote Ischemic Conditioning for Efficacy in Patients With Aneurysmal Subarachnoid Hemorrhage

Not yet recruiting NA Last updated 10 July 2025

What this trial tests

NA trial testing Sham RIC in Subarachnoid Hemorrhage in 500 participants. Not yet recruiting.

Timeline

1 July 2025

Primary endpoint
1 January 2026

1 April 2026

Quick facts

Lead sponsor	Beijing Tiantan Hospital
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	500
Start date	1 July 2025
Primary completion	1 January 2026
Estimated completion	1 April 2026
Sites	1 location across China

Drugs / interventions tested

• Sham RIC
• Remote Ischemic Conditioning treatment instrument

Conditions studied

• Subarachnoid Hemorrhage — all drugs for Subarachnoid Hemorrhage →
• Cerebrovascular Disorders — all drugs for Cerebrovascular Disorders →
• Brain Diseases — all drugs for Brain Diseases →
• Stroke — all drugs for Stroke →

Sponsor

Beijing Tiantan Hospital

Who can join

Adults 18 to 80, any sex, with Subarachnoid Hemorrhage or Cerebrovascular Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Several recent large-scale clinical trials aimed at improving subarachnoid hemorrhage(SAH) outcomes have concluded with negative results, failing to enhance the prognosis for these patients. Consequently, there is an urgent demand for novel treatment strategies and approaches to address the challenges posed by SAH.

Remote ischemic conditioning(RIC) has gained considerable attention in the treatment of stroke, particularly ischemic stroke, with numerous studies demonstrating its potential to enhance neurological outcomes compared to conventional treatments alone.RIC for the treatment of SAH is an investigative strategy in its initial stages. The neuroprotective effects of RIC, particularly its potential to preserve cranial nerve function and ameliorate neurological deficits, confer significant value in the treatment of SAH patients.

The precise manner in which SAH patients may benefit from RIC treatment, and the mechanisms by which it improves neurological function, remain to be fully understood. Consequently, randomized controlled trials are necessary to validate the efficacy of RIC in this patient population and to delineate the optimal therapeutic protocols for its application.

Based on the above discussion, this study aims to explore the efficacy and safety of RIC in the treatment of SAH.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. Beyond the bleed: complications after aneurysmal subarachnoid hemorrhage. Pathophysiology, clinical implications, and management strategies: a review.
   Busl KM, Bogossian EG, Claassen J, Helbok R, et al · · 2025 · cited 4× · PMID 41029753 · DOI 10.1186/s13054-025-05640-z
2. Remote ischemic conditioning for safety, feasibility and preliminary efficacy of patients with aneurysmal subarachnoid hemorrhage after aneurysm clipping, design, and protocol for an open-label, evaluator blinding randomized controlled trial.
   Xu L, Jin T, Niu H, Yin Y, et al · · 2025 · PMID 41356238 · DOI 10.3389/fneur.2025.1650773
3. Remote ischaemic conditioning for efficacy in patients with aneurysmal subarachnoid haemorrhage (REPAIR): protocol for a multicentre, randomised, double-blind, sham-controlled, parallel-group trial.
   Jin T, Niu H, Liu L, Yin Y, et al · · 2025 · PMID 40789732 · DOI 10.1136/bmjopen-2025-101350